Maja Lindegaard Moensted
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maja Lindegaard Moensted has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Sophie Lewis
The University of Sydney
16 shared publications - Leslie Dubbin
Department of Social and Behavioral Sciences, University of California, San Francisco, CA, USA
14 shared publications - Karen Willis
Victoria University
13 shared publications - Lorraine Smith
The University of Sydney
13 shared publications - Anne Rogers
University of Southampton
11 shared publications - Marika Franklin
The University of Sydney
10 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 157 (Pt A) , 105499
From custody to abandonment: Conceptualising Aboriginal people's drug treatment discontinuation after release
- 10 September 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 157 (Pt A) , 105499
Open AccessFrom custody to abandonment: Conceptualising Aboriginal people's drug treatment discontinuation after release
- 11 July 2026
- Published by Elsevier in Health & Place
- Vol. 100, 103712
Lonely in place? The intersection of loneliness and place in the chronic illness experience
- 11 July 2026
- Published by Elsevier in Health & Place
- Vol. 100, 103712
Lonely in place? The intersection of loneliness and place in the chronic illness experience
- Open Access
- 18 February 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (2) , e70096
Experiences of People Who Discontinue Long‐Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia
Introduction: Among other benefits, opioid agonist treatment (OAT; methadone and buprenorphine) is protective against overdose for people with opioid use disorder following release from custody. Long‐acting injectable buprenorphine (LAIB) is safe with an apparent low risk of diversion relative to other OAT formulations in correctional settings and may become a preferred OAT formulation in this setting. Factors that influence retention in LAIB post‐release are unknown. Method: People receiving LAIB in nine New South Wales prisons were consented to participate in a survey designed to explore treatment experiences post‐release. Participants who reported ceasing LAIB within 12 weeks of release were invited to complete an in‐depth interview using a semi‐structured guide via phone or secure videoconference in the community, or in custody if reincarcerated. Interviews were transcribed verbatim, and data analysed using iterative categorisation and thematic analysis. Results: A total of 31 participants who ceased LAIB within 12 weeks following release from custody were interviewed. Mean age was 34 years (SD 9), 24 were male and 16 identified as Aboriginal People. Key themes regarding treatment cessation were misinformation and lack of treatment education, limited transition supports for housing, mental health and illicit substance use, and changing treatment benefits between the custody and community contexts including illicit substance preferences and side effects. Discussion and Conclusions: Numerous personal experiences and psychosocial factors impacted participant motivations and capacity to continue LAIB post‐release. Understanding and addressing these factors is necessary to support treatment retention and increase community‐based program acceptability and continuation in this population.
- 18 February 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (2) , e70096
Open AccessExperiences of People Who Discontinue Long‐Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia
Introduction: Among other benefits, opioid agonist treatment (OAT; methadone and buprenorphine) is protective against overdose for people with opioid use disorder following release from custody. Long‐acting injectable buprenorphine (LAIB) is safe with an apparent low risk of diversion relative to other OAT formulations in correctional settings and may become a preferred OAT formulation in this setting. Factors that influence retention in LAIB post‐release are unknown. Method: People receiving LAIB in nine New South Wales prisons were consented to participate in a survey designed to explore treatment experiences post‐release. Participants who reported ceasing LAIB within 12 weeks of release were invited to complete an in‐depth interview using a semi‐structured guide via phone or secure videoconference in the community, or in custody if reincarcerated. Interviews were transcribed verbatim, and data analysed using iterative categorisation and thematic analysis. Results: A total of 31 participants who ceased LAIB within 12 weeks following release from custody were interviewed. Mean age was 34 years (SD 9), 24 were male and 16 identified as Aboriginal People. Key themes regarding treatment cessation were misinformation and lack of treatment education, limited transition supports for housing, mental health and illicit substance use, and changing treatment benefits between the custody and community contexts including illicit substance preferences and side effects. Discussion and Conclusions: Numerous personal experiences and psychosocial factors impacted participant motivations and capacity to continue LAIB post‐release. Understanding and addressing these factors is necessary to support treatment retention and increase community‐based program acceptability and continuation in this population.
- Open Access
- 23 December 2025
- Published by Elsevier in Health & Place
- Vol. 97, 103598
Navigating contested terrain: How place meanings shape health after homelessness
- 23 December 2025
- Published by Elsevier in Health & Place
- Vol. 97, 103598
Open AccessNavigating contested terrain: How place meanings shape health after homelessness
- 2 November 2025
- Published by Springer Nature
- p. 135-168
Feeling at Home, Having Places to Go: The Place Dimensions of Loneliness
- 2 November 2025
- Published by Springer Nature
- p. 135-168
Feeling at Home, Having Places to Go: The Place Dimensions of Loneliness
- 2 November 2025
- Published by Springer Nature
- p. 185-201
Loneliness in Chronic Illness Care: Health and Community Care Professional Perspectives
- 2 November 2025
- Published by Springer Nature
- p. 185-201
Loneliness in Chronic Illness Care: Health and Community Care Professional Perspectives
- 2 November 2025
- Published by Springer Nature
- p. 113-134
Bridging Connection? Digital Spaces and Communities
- 2 November 2025
- Published by Springer Nature
- p. 113-134
Bridging Connection? Digital Spaces and Communities
- 2 November 2025
- Published by Springer Nature
- p. 29-49
Insignificant, Irrelevant, and Alienated: Types of Loneliness While Navigating Chronic Illness
- 2 November 2025
- Published by Springer Nature
- p. 29-49
Insignificant, Irrelevant, and Alienated: Types of Loneliness While Navigating Chronic Illness
- 2 November 2025
- Published by Springer Nature
- p. 169-183
Loneliness of Care, Care for the Lonely
- 2 November 2025
- Published by Springer Nature
- p. 69-91
Navigating Relationships and Support with Chronic Illness: The Work of Connection
- 2 November 2025
- Published by Springer Nature
- p. 69-91
Navigating Relationships and Support with Chronic Illness: The Work of Connection